A Retrospective Cohort Study of Infusion Reactions Due to Vectibix
- Conditions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 141
- Registration Number
- NCT01156090
- Locations
- 🇺🇸
St. Louis Cancer Care, Chesterfield, Missouri, United States
🇺🇸South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01154335
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01121939
- Locations
- 🇺🇸
Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸Grand Rapids Oncology Program, Grand Rapids, Michigan, United States
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT01113632
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸South Carolina Oncology Associates, Columbia, South Carolina, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT01076504
- Locations
- 🇺🇸
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-01-26
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 59
- Registration Number
- NCT01056276
- Locations
- 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸Los Robles Hospital and Medical Center, Thousand Oaks, California, United States
🇺🇸Florida Cancer Specialists, Ft. Myers, Florida, United States
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 283
- Registration Number
- NCT01048099
- Locations
- 🇺🇸
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Florida Cancer Specialists, St. Petersburg, Florida, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
- Conditions
- Interventions
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01042288
- Locations
- 🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 22
- Registration Number
- NCT01035658
- Locations
- 🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT01033032
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸Berks Hematology Oncology Associates, West Reading, Pennsylvania, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States